logo

Hoth Therapeutics, Inc. (HOTH)



Trade HOTH now with
  Date
  Headline
6/9/2022 8:21:01 AM Hoth Therapeutics Announces Extension Of Washington University Alzheimer's Mouse Model Study With HT-ALZ
5/3/2022 8:16:31 AM Hoth:Preliminary Efficacy Findings From Phase 1b Trial Of BioLexa Lotion Shows Improvement In Atopic Dermatitis Symptoms
4/11/2022 11:42:41 PM Hoth Therapeutics Announces Pricing Of 8.23 Mln Shares At $0.85/Shr, Priced At-the-market
3/22/2022 9:51:09 AM Hoth Therapeutics Says Successfully Completed Manufacturing Feasibility Of The HT-KIT Drug Substance
3/11/2022 8:05:40 AM Hoth Therapeutics : FDA Grants Orphan Drug Designation To Cancer Therapeutic HT-KIT To Treat Mastocytosis
2/7/2022 8:13:05 AM Hoth Therapeutics Announces Presentation Of HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data
1/31/2022 8:18:51 AM Hoth Appoints John Cirrito And Carla Yuede To Scientific Advisory Board
1/4/2022 8:09:00 AM Hoth Reports HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid ? In Alzheimer's Disease; Stock Up
12/21/2021 8:00:23 AM Hoth Announces Submission Of Orphan Drug Designation Request For HT-KIT To Treat Mastocytosis
11/30/2021 8:12:49 AM Hoth Says Enrollment And Dosing In Second Cohort In Phase 1b Human Trial For Atopic Dermatitis Under Way
11/16/2021 8:33:11 AM Hoth Therapeutics Announces Agreement To Further Develop Novel MRNA Cancer Therapeutic HT-KIT
11/8/2021 8:42:35 AM Hoth Signs API And Drug Product Contracts With WuXi STA To Advance Manufacturing Of HT-KIT Cancer Therapeutic
10/12/2021 10:03:28 AM Hoth Therapeutics Gets Approval To Commence Cohort 2 In Trial Of BioLexa For Treatment Of Atopic Dermatitis Patients
9/21/2021 10:07:19 AM Hoth Submits To Ethics Committee For Approval To Initiate Patient Cohort 2 In BioLexa Clinical Trial
9/8/2021 8:10:55 AM Hoth Therapeutics Announces Positive Phase 1b Results From First Cohort Of Patient Trial Of BioLexa